Connect with us

Breaking

First Clinical Site Active in Phase 2 Trial as Tenax Therapeutics Aims to Fill Gap in Treatment for Pulmonary Hypertension

Published

on

As it grows in diagnoses, pulmonary hypertension with preserved ejection fraction (PH-HFpEF) remains woefully underserved, with no FDA-approved drugs to treat the disease. Indeed, there are several options for therapeutics specific to pulmonary arterial hypertension (PAH), but there is a clear differentiation between the two conditions supported by clinical data that what works for PAH does not work for PH-HFpEF.

To that point, the team at specialty pharma Tenax Therapeutics (NASDAQ; TENX) is working to develop levosimendan to become the first approved treatment in the U.S. for PH-HFpEF. Levosimendan, a calcium sensitizer that works through a triple mechanism of action, was originally developed as an IV drug for acute decompensated heart failure, ultimately earning approval in 60 countries outside the U.S. for the indication. In 2013, Tenax acquired the rights to develop and commercialize levosimendan in North America from Phyxius Pharma.

The company is looking to leverage data from clinical studies in patients with right heart failure and pulmonary hypertension that suggest levosimendan may be an effective therapy in treating PH-HFpEF. The therapeutic effects of levosimendan are further supported by over one million patients being treated with the drug in the countries where it is approved.

More than 2.5 million Americans suffer from HFpEF, with pulmonary hypertension present in the majority of these patients. Mortality rates are high – up to 50 percent at five years – and the patients must cope with a poor quality of life owing to very limited exercise capacity.

PH-HFpEF is categorized in Group 2 of the World Health Organization’s breakdown of pulmonary hypertension (PH), whereas PAH is categorized in Group 1. This distinction is important in many ways, including market opportunity. For instance, when it comes to total PH, Group 1 comprises only 3% of prevalence; Group 2 accounts for 68%. Furthermore, there are a litany of drugs approved by the FDA for Group 1 (generating $5+ billion in annual sales), including PDE5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators and prostacyclins. Efficacy is not established in Group 2 for any of these, leaving a gaping void in chronic care.

Tenax recently activated the first clinical site, Stanford University School of Medicine, in its Phase 2 trial of levosimendan for PH-HFpEF. The study is being referred to under the acronym “HELP,” short for Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF. The study, expected to enroll 36 adult patients, has a primary outcome comparing the levosimendan group against the placebo group with respect to the change from baseline Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise after six weeks of therapy.

Multiple secondary outcomes will also be evaluated, including change in Cardiac Index at rest and with exercise, exercise duration via 6-minute walk test and more. In aggregate, the data is

expected to better define criteria for a Phase 3 trial of levosimendan for PH-HFpEF patients in the future.

According to the study’s listing on clinicaltrials.gov, Tenax is targeting completion of the Phase 2 trial in November 2019.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from IRTH Communications for content creation, advertising and distribution services related to this material.

Breaking

A New Spin on CBD: Quanta Upping the Game with Bioenergy

Published

on

Cannabidiol, or CBD for short, a component of cannabis, is all the rage today, underscored by President Trump last week signing the U.S. Farm Bill 2018 into law. After decades of being held to the same standard as cannabis that contains THC, hemp is finally removed from the Controlled Substance Act, effectively making hemp-based CBD legal at the federal level.

Cannabis and hemp are similar with one major differentiator: THC (tetrahydrocannabinol), the cannabinoid in cannabis responsible for the psychoactive high, or “stoned” feeling from ingesting marijuana. Hemp contains little to no THC, but does contain CBD, a non-psychotropic cannabinoid widely acclaimed for a litany of medical uses, including applications for hard-to-treat diseases like epilepsy and PTSD, as well as more casual uses, such as skincare.

With the passage of the Farm Bill, hemp-based CBD – which still falls under the regulatory scrutiny of the U.S. Food and Drug Administration – is legal for a bevy of development activity.

The scientists at Quanta (OTC: QNTA) are putting a new spin on cannabinoids, specifically CBD, amplifying the benefits by using the combination of quantum physics and biochemistry to increase bioenergy within the cell. As explained in a corporate video, this produces a better chemical reaction in the body.

The science is based in part on principles of quantum physics proving that everything in the universe is energy and has its own vibration, or vibrational frequency more specifically, including cannabinoid receptors. Cannabis, by virtue of its properties as a plant, is losing vibrational power every day. Quanta uses a patented technology to retrain the vibrations within cannabinoids, which raises their bioenergy, until they have identical frequencies to the body’s cannabinoid receptors.

When these matching frequencies combine, the highest possible response is the result and the CBD is absorbed into the body more efficiently with little to no side effect. This takes each element in Quanta’s formula to peaks levels of performance, meaning the user enjoys a better experience in reduction of things like pain, inflammation, stiffness and anxiety that CBD is heralded for delivering.

Quanta’s lead product is CBD Muscle Rub, a combination of 13 natural elements including turmeric, arnica and polarized CBD, administered topically for the relief of muscle and joint pain and stiffness.

While the initial focus is on hemp-based CBD, the technology is available for licensing or product development that can be applied to all types of plant matter to enhance energy in naturally occurring molecules utilizing the same properties of the Law of Vibration and the fact that humans are bio-electric beings. In addition to the effect on muscles and joints, the complete Quanta process, which involves identifying natural elements by their frequency and using magnetic and electric frequencies to illicit changes at the sub-atomic level to make the

targeted molecules move faster to create a bond in receptors for an energized and frictionless experience, have been shown to significantly reduce anxiety, paranoia, cognitive haze and drowsiness.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from IRTH Communications for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

One Million Users and Counting: MassRoots Connecting Consumers and Cannabis Dispensaries

Published

on

The passage of the 2018 U.S. Farm Bill, officially called the Agricultural Improvement Act of 2018, is expected to bolster the already rapidly emerging hemp industry as it finally legalized industrial hemp and cannabidiol (CBD) that comes from hemp. The signing of the bill has been widely cheered by cannabis industry advocates that argue the broad reaching medicinal benefits of CBD, ranging from anti-aging properties to controlling seizures.

Hemp is defined as cannabis (Cannabis sativa L.) and derivatives of cannabis with extremely low (less than 0.3 percent on a dry weight basis) concentrations of the psychoactive compound delta-9-tetrahydrocannabinol (THC). In layman’s terms, it’s the type of cannabis that doesn’t have the “high” due to THC that is commonly associated with marijuana. For decades, hemp, regardless of its non-intoxicating nature, has been illegal as a Schedule I drug under the Controlled Substance Act and only allowed to be grown under specific conditions for research purposes as allowed by state law. The Farm Bill changed that.

Little credence has been given to the therapeutic effects of CBD by many pundits due to the lack of clinical research that has been limited because of federal prohibition. However, with medical marijuana now legal in 33 U.S. states – and recreational marijuana legal in 10 states and the District of Columbia – there is no shortfall of advocates touting its benefits.

Further, the U.S. Food and Drug Administration this year gave marketing approval to GW Pharmaceuticals’ Epidiolex, a CBD therapy for treating rare types of epilepsy, making it the first cannabis-based drug ever given the green light, which throws a dart into the notion that CBD has no medical use.

MassRoots (OTCQB: MSRT) is a leading technology platform for the regulated cannabis industry centered on information and connectivity that allows businesses to reach consumers and consumers to make educated purchases based on consumer reviews of thousands of cannabis products. The platform has a wide influence with more than one million registered users.

With the trend towards CBD gaining momentum, MassRoots is preparing to launch a new review and e-commerce platform focused on CBD products. The existing platform has already generated “tens of thousands” of reviews on CBD products, information the company believes will be able to expand its audience by being presented separately from products containing THC. Given its large user base and shift in hemp laws effective January 1, 2019, the opportunity for an online platform offering CBD products is not going overlooked by MassRoots.

On the business side, the company offers its MassRoots for Business portal. The fully-integrated platform was recently loaded with new features and analytics for its dispensary customers expected to drive additional traffic and provide greater insight into consumer behavior. Business clients pay a monthly fee for listing on the MassRoots platform, as well as fees for the company’s new WeedPass Rewards program that enables consumers to earn

rewards (for example, tickets to movies and sporting events) by shopping at dispensaries participating in WeedPass.

Upon the acquisition of the WeedPass.com domain this month, MassRoots initiated an online marketing campaign, comprised of leading cannabis social media influencers on Instagram, SnapChat, Twitter and MassRoots.

Launched only a few months ago, more than 100 dispensaries are already participating in the WeedPass program in the Los Angeles and Denver markets, driving over $120,000 in sales to those dispensaries. There is still plenty of headroom for expansion as measured by New Frontier Financial’s estimate that there are more than 2,500 regulated dispensaries in the U.S.

To that end, MassRoots says it intends to widen the availability of WeedPass outside of California and Colorado into every state with a regulated cannabis market. With Michigan legalizing recreational marijuana and Utah and Missouri making medical marijuana legal by ballot measure last month, the company’s addressable market just got a little bigger.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from IRTH Communications for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

Selling Convenience in a Bottle: Driven Leading Public Cannabis Delivery Companies

Published

on

The world today has become increasingly “on demand.” Whether it is a movie, laundry soap or food, people want what they want, and they want it delivered to their doorstep right now. A $6 billion valuation for GrubHub and Amazon growing into one of the world’s biggest companies speak clearly to macro-trends favoring the on-demand dynamic.

With cannabis legalization sweeping the nation, why would we expect anything different for this consumer product? The answer is: “We shouldn’t.” To that point, as regulators have been hammering out guidelines to ensure safety and standardization, select companies have been gaining traction with their cannabis delivery businesses as the market starts to grow.

In the U.S., Driven (OTC: RBOS), which likens itself to “GrubHub for cannabis,” is the only publicly traded cannabis delivery service. With plans to expand into Nevada, Arizona and Michigan in 2019, the company currently operates exclusively throughout its home state of California, a market where medical marijuana has been legal for about 20 years and recreational cannabis was legalized at the start of 2018. California is hands down the market stalwart, with Arcview Market Research and its partner BDS Analytics forecasting the legal cannabis market to reach $5.1 billion in the next year.

More broadly, the industry research group sees the U.S. market climbing three-fold to $23.3 billion in the five years to 2022. With the latest ballots in November, recreational marijuana is legal in 10 states and the District of Columbia, while medicinal cannabis is allowed in 33 states.

Against that backdrop, Driven CEO Chris Boudreau believes that cannabis delivery represents a $600 million opportunity for the company, according to a presentation at the annual LD Micro Conference earlier this month. A commercial banking executive by trade, Boudreau found success in his foray into cannabis a decade ago, helping to build California’s Kindest into one of the largest retail delivery cannabis companies and Sunstone Distribution into the first statewide wholesale cannabis distribution company.

Driven differentiates itself from rival Eaze through its last-mile delivery model. More specifically, Driven operates through a “Bag and Carry” model, where it can work with any and all dispensaries to deliver specific product ordered by the dispensary’s customers. Eaze utilizes a “Mobile Dispensary” model, where it works with only one dispensary in a local market, shuttling product around in a manner similar to an ice cream truck (although obviously not advertising its vehicles as such).

Driven uses a complete tracking system to ensure regulatory compliance and security. A turnkey infrastructure allows Driven to get a dispensary up and running with a delivery service in under two weeks. Now more than just a delivery service, the tech company earlier this year folded-in its own marketing and marketplace, for which it charges the dispensary a premium for initiating sales.

This has catalyzed sales since being rolled out. In May, for example, 169 deliveries were initiated by the dispensary and 22 were pushed through by Driven. During August, those figures rose to 469 and 134, respectively.

The efforts have resulted in approximately 4,500 deliveries in the last six months for Delivered.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from IRTH Communications for content creation, advertising and distribution services related to this material.

Continue Reading

Most Popular